Bio-Rad Laboratories B
BIO.B
Bio-Rad Laboratories B (BIO.B) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.62
- EPS estimate
- $1.78
- EPS surprise
- +47.05%
- Revenue surprise
- +4.19%
- Revenue
- $651.0M
- Revenue estimate
- $624.8M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $1.78 | $2.62 | +47.05% | $651.0M | SEC |
| Q1 2026 | Apr 30, 2026 | $2.01 | $1.89 | −6.08% | $592.1M | SEC |
| Q4 2025 | Feb 12, 2026 | $2.69 | $2.51 | −6.74% | $693.2M | SEC |
| Q3 2025 | Oct 29, 2025 | $1.89 | $2.26 | +19.47% | $653.0M | SEC |
| Q2 2025 | Jul 31, 2025 | $1.75 | $2.61 | +49.23% | $651.6M | SEC |
| Q1 2025 | May 1, 2025 | $1.82 | $2.54 | +39.69% | $585.4M | SEC |
| Q4 2024 | Feb 13, 2025 | $2.86 | $2.90 | +1.26% | $667.5M | SEC |
| Q3 2024 | Oct 30, 2024 | $1.13 | $2.01 | +78.14% | $649.7M | SEC |
| Q2 2024 | Aug 1, 2024 | $2.05 | $3.11 | +51.40% | $638.5M | SEC |
| Q1 2024 | May 7, 2024 | $2.17 | $2.29 | +5.36% | $610.8M | SEC |
| Q4 2023 | Feb 15, 2024 | $2.84 | $3.10 | +9.23% | $681.2M | SEC |
| Q3 2023 | Oct 26, 2023 | $2.76 | $2.33 | −15.72% | $632.1M | SEC |
| Q2 2023 | Aug 3, 2023 | $2.64 | $3.00 | +13.82% | $681.1M | SEC |
| Q1 2023 | May 4, 2023 | $3.63 | $3.34 | −7.89% | $676.8M | SEC |
| Q4 2022 | Feb 16, 2023 | $3.48 | $3.31 | −4.78% | $730.3M | SEC |
| Q3 2022 | Oct 27, 2022 | $2.70 | $2.60 | −3.87% | $680.8M | — |
| Q2 2022 | Jul 28, 2022 | $2.72 | $3.38 | +24.26% | $691.1M | — |
| Q1 2022 | Apr 28, 2022 | $3.34 | $4.94 | +47.90% | $700.1M | — |
| Q4 2021 | Feb 10, 2022 | $2.82 | $3.21 | +13.70% | $732.8M | — |
| Q3 2021 | Oct 28, 2021 | $2.31 | $3.71 | +60.61% | $747.0M | — |
Quarterly revenue
Frequently asked questions
When did Bio-Rad Laboratories B (BIO.B) last report earnings?
Bio-Rad Laboratories B last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did BIO.B beat earnings estimates?
Yes. Bio-Rad Laboratories B reported EPS of $2.62 for Q2 2026 against a $1.78 estimate — a 47.05% beat.
How much revenue did BIO.B report last quarter?
Bio-Rad Laboratories B reported $651.0M in revenue for Q2 2026, against a consensus estimate of $624.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.